

**RECEIVED  
CENTRAL FAX CENTER**

S/N 10/729,276

APR 26 2005

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: HAQUE ET AL. Examiner: Spivack, P.G.  
Serial No.: 10/729,276 Group Art Unit: 1614  
Filed: DECEMBER 3, 2003 Docket No.: 12695.13USD2  
Title: TREATMENT OF CEREBROVASCULAR DISEASE

**CERTIFICATE UNDER 37 CFR 1.8(h):**

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on April 26, 2005.

By:

*Carmen Grimes*

Name:

CARMEN GRIMES

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(c))**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted after the mailing date of a first Office Action on-the-merits or a first Office Action after filing a Request for Continued Examination under 37 C.F.R. § 1.114 or a CPA under 37 C.F.R. § 1.53(d), but before the mailing date of: i) a final action under 37 C.F.R. § 1.113; ii) a Notice of Allowance under 37 C.F.R. § 1.311; or iii) an action that otherwise closes prosecution on the application. **Please charge Deposit Account No. 13-2725 in the amount of \$180 under 37 C.F.R. § 1.17(p) for consideration of the items listed on the enclosed Form 1449.**

A copy of any foreign patent document or "Other Document" listed on the Form 1449 is enclosed, in accordance with 37 C.F.R. § 1.98(a)(2). Because this application was filed after June 30, 2003, copies of the U.S. Patents and U.S. patent publications listed on the enclosed Form 1449 are not provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a

reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.


Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.


Respectfully submitted,

MERCHANT & GOULD P.C.  
P.O. Box 2903  
Minneapolis, Minnesota 55402-0903  
(612) 332-5300

Date:

4/26/2005

  
\_\_\_\_\_  
Ronald A. Daignault  
Reg. No. 25,968  
RDaignault:BRD:mls



Date Mailed: April 22, 2005

Sheet 1 of 1

<b>FORM 1449*</b>  <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b>  (Use several sheets if necessary)	<b>Docket Number:</b> 12695.13USD2	<b>Application Number:</b> 10/729,276
	<b>Applicant:</b> HAQUE ET AL..	
	<b>Filing Date:</b> 12/03/2003	<b>Group Art Unit:</b> 1614

[illegible]

**23552**

PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
<p>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.</p>	

\*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE